Inaret rospective analysis of 4374 patients enrolled in the Multicenter Study of Perioperative Ischemia Research Group international database, aprotinin use was associated with a higher incidence of adverse outcome, (renal, neurological, and cardiac) in patients undergoing primary coronary artery bypass surgery (CABG), compared to patients receiving tranexamic acid, ⑀-aminocapronic acid or control group patients. 1 From the same database, a 5-yr follow-up was recently published. 2 The authors concluded that, with regard to the association between aprotinin, end-organ failure and long-term mortality, the continued use of aprotinin seems not to be prudent. "Safer alternatives," such as tranexamic acid or ⑀-aminocapronic acid, should be used during CABG.
Both studies had an inconsistent demographic bias, especially concerning the patients' preoperative risk, and had to be mathematically corrected by propensity score adjustment. The possible influence of unmeasured variables cannot be excluded, and the question remains whether the increased prevalence of adverse outcomes is a consequence of different perioperative risk factors.
For many years at our institution aprotinin has been used in almost every patient undergoing cardiac surgery with extracorporeal circulation. 3 As a consequence of the serious concerns about the safety of aprotinin, we decided to completely stop using aprotinin in February 2006, and to use tranexamic acid instead, as the antifibrinolytic drug of choice during cardiac surgery.
This consequent treatment with one of the antifibrinolytic drugs offered us the opportunity to create two treatment groups of our consecutive patients without any preselection. In this study, we compared data of a 5-mo period of administering tranexamic acid with data of the preceding 5 mo of aprotinin administration in almost 1200 consecutive adult cardiac surgery patients undergoing extracorporeal circulation with regard to blood loss, cardiac, renal, and neurological complications, as well as 30-day, and 1-yr mortality.
Although not randomized, this study meets most criteria of a randomized clinical trial without the need to use statistical methods for risk adjustment, in contrast to the other recently published studies on this topic.
METHODS
The study was approved by the Ethical Committee of the Technical University Munich (Germany); the requirement for written informed consent was waived by the board. After approval, we analyzed the perioperative data of all adult patients undergoing cardiac surgery using cardiopulmonary bypass (CPB) between September 2005 and June 2006 (n ϭ 1239). Patients were excluded if they did not receive any antifibrinolytic therapy, received multiple drugs, or the administered dose of the antifibrinolytic drug was not sufficient according to our institutional protocol (total dose Ͻ4 ϫ 10 6 kallikrein inhibiting units (KIU) aprotinin or 4 g tranexamic acid, respectively). If a patient underwent reoperation for nonbleeding reasons during the same admission, only data of the first operation were included in the analyses. After exclusion, the study cohort contained data of 1188 consecutive patients (Fig. 1) . Data of the patients were prospectively collected in the clinical database as part of the national quality assurance project in cardiac anesthesia and surgery. Laboratory values were extracted from the database of the clinical laboratory.
Until February 2006, all patients undergoing cardiac surgery with CPB were treated with full-dose aprotinin (Trasylol; Bayer, Leverkusen, Germany) according to the Hammersmith protocol (Group A). The Hammersmith protocol consists of a bolus of 2 ϫ 10 6 KIU aprotinin administered at the beginning of CPB, followed by a continuous infusion of 0.5 ϫ 10 6 KIU/h until chest closure; 2 ϫ 10 6 KIU is added to the prime of the CPB equipment. From February 2006 onward, aprotinin was completely replaced by tranexamic acid (Cyklokapron; Pfizer, Karlsruhe, Deutschland) (Group T). Tranexamic acid was administered according to the institutional protocol: 2 g was administered at the beginning of CPB and then as a continuous infusion at a rate of 0.5 g/h until chest closure; 2 g was added to the prime of the CPB equipment. We compared perioperative data of the patients from the first 5-mo period of using tranexamic acid (Group T, n ϭ 592) with data of patients from the preceding 5 mo of aprotinin administration (Group A, n ϭ 596). All other aspects of the surgical and anesthetic management remained unchanged.
A standard CPB setting was used. After crossclamping of the aorta, either 1500 mL of cold crystalloid cardioplegic solution (Bretschneider ϭ Custodiol; Kö hler Chemie, Alsbach-Hahnlein, Germany) for any surgery involving valves or warm blood-cardioplegia (CABG surgery only) was used for cardiac arrest. Transfusion triggers used were a hematocrit decrease to Ͻ18% on CPB or Ͻ24% during the postoperative course, or if the patient showed clinical signs indicating the need for a higher oxygen supply. Inotropic support was defined as the continuous infusion of at least two of the following: more than 5 g ⅐ kg ⅐ min Ϫ1 dopamine or dobutamine, or epinephrine or milrinone, respectively. Vasopressor therapy was defined as the application of norepinephrine of at least 500 g/h.
We analyzed the main demographic data, the medical history data, the intraoperative data, and the type of surgery. Postoperative blood loss was measured as chest-tube output at 6, 12, and 24 h after surgery. The amount of transfused allogenic blood products and reoperation for bleeding were also recorded. Postoperative renal dysfunction required a serum creatinine level of Ͼ1.3 mg/dL with an increase over baseline of at least 0.5 mg/dL; renal failure was defined as dysfunction requiring dialysis. Cardiac complications were new persistent atrial fibrillation (new atrial fibrillation continuing until discharge from the intensive care unit), acute myocardial infarction (AMI; new Q-waves, persistent ST-segment or T-wave changes and CK-MB higher than three times the upper limit of normal range of our institution protocol, i.e., Ͼ80 U/L), 29 and heart failure (need for inotropic support and intraaortic ballon pump). Neurological events, defined as new seizure or stroke/transitory ischemic attack, were clinically diagnosed; stroke was confirmed by computed tomography scan.
Mortality (all-cause death) was assessed 30 days and 1-yr after surgery. Foreign patients were primarily excluded from follow-up (primary loss). A questionnaire was sent to all patients who were not taking part in routine examination at 1-yr after surgery. If necessary, the patients' cardiologists or the local authorities were contacted. Nonresponders were also excluded (secondary loss).
We analyzed data of the whole cohort together (ALL). For post hoc analysis, this collective was split in three subgroups according to the type of surgery: primary CABG, primary valve surgery (VALVE); i.e., left heart valve surgery (mitral and/or aortic valve), and high risk surgery (HIGH RISK) operations for bleeding, e.g., combined and redo operations, aortic surgery, etc. (Table 1) .
Continuous data are presented as mean Ϯ sd (SD), categorical variables as number (N), and incidence (%). Parameters were compared between Group A and Group T using Mann-Whitney U-test for continuous variables and 2 test for categorical variables. For 2 analysis, the effective total sample size to achieve a power level of 0.8 (␣ ϭ 0.05, estimated effect size ϭ 0.2, df ϭ 1) was 197 (GPOWER for MS-DOS, Franz
Faul & Edgar Erdfelder, Bonn, Germany). The difference in mortality between the treatment groups was assessed by Kaplan-Meier analysis and Mantel-Cox log-rank test. The results of the two-sided tests were considered significant if the P value was Ͻ0.05. The statistical analyses were performed by SPSS for Windows 14.0 statistical software package (SPSS Inc., Chicago, IL).
RESULTS
There was similar distribution of type of surgery in the treatment groups ( Table 1 ). The main pre-and intraoperative data are presented in Table 2 . The only difference in the entire cohort was that more patients were medicated with clopidogrel in Group A. In the subgroups, we found some minor differences ( Table  2. ). The 10 most experienced surgeons and anesthesiologists performed 92% and 83% of the operations in Group T, and 93% and 85% in Group A, respectively.
In ALL patients, the postoperative blood loss and the postoperative transfusion of red blood cells and fresh frozen plasma were significantly decreased in Group A (Table 3. ). Subgroup analyses showed significantly less blood loss after administration of aprotinin at all time points in all subgroups, whereas the amount of transfused blood products was significantly smaller only in the VALVE subgroup postoperatively (Table 3) .
Outcome data of the patients are presented in Table  4 . Analyzing ALL patients, the incidences of persistent atrial fibrillation and seizure were significantly higher in Group T; the incidence of AMI was higher in Group A. Subgroup analyses showed that in the primary CABG group there were more AMI and renal dysfunction after aprotinin treatment. Administration of tranexamic acid was associated with a higher incidence of seizure, atrial fibrillation, and renal failure in the VALVE subgroup, and with a higher incidence of seizure in the HIGH RISK patients. Data are presented as mean Ϯ standard deviation (SD) or number and incidence (%). Significant values are indicated by bold. ACE ϭ angiotensin-converting enzyme; AoX ϭ aorta cross clamp; ASA score ϭ American Society of Anesthesiologists score; COPD ϭ chronic obstructive pulmonary disease; CPB ϭ cardiopulmonary bypass; DM ϭ diabetes mellitus; EF ϭ ejection fraction; GFR ϭ glomerular filtration rate; HB ϭ hemoglobin; MI ϭ myocardial infarction; NYHA class ϭ New York Heart Association class; PCI ϭ percutanous coronary intervention. a Only the significant differences of the subgroups are presented. b The estimated glomerular filtration rate (GFR) was calculated according to the modification of diet in renal disease equation. 4 Follow-up for mortality was conducted in 96.5% of the patients. Mortality in ALL patients showed no significant difference between the treatment groups. We have not found any significant difference in 30-day mortality in the subgroups, but 1-yr mortality was significantly higher in the HIGH RISK group after aprotinin treatment (Table 5 , Fig. 2 ).
DISCUSSION
As every consecutive patient was included in our analysis, we generated an unselected population with only minor differences in the preoperative and intraoperative data. We assumed that the unmeasured variables were also comparable and therefore, no mathematical adjustment, such as propensity score method, was necessary for further analysis. This is an important difference to recently published retrospective studies.
1,2,5-7
The efficacy of antifibrinolytic drugs on blood loss and perioperative transfusion of donor blood has been described. 8 The blood-sparing effect of aprotinin was often superior to that of tranexamic acid 9,10 and aminocapronic acid, but not always. 6, 11, 12 Our data showed that patients receiving aprotinin during cardiac surgery had significantly lower postoperative blood loss compared to patients receiving tranexamic acid. This benefit was detected in the entire cohort and all subgroups, but it had no effect on the amount of transfusion in the CABG and HIGH RISK patients.
Thus, it is still questionable whether the statistically smaller blood loss in Group A is really clinically relevant.
Besides the well documented reduction of blood loss, antifibrinolytic drugs might have some unexpected effects, which were often not assessed in the studies focusing on postoperative blood loss and transfusion rates only. Some investigators have demonstrated that aprotinin decreases mortality in cardiac surgery 13 and reduces the incidences of stroke or encephalopathy. 14, 15 Others have demonstrated an increased risk of myocardial infarction, stroke or encephalopathy, renal failure, 1 renal failure only, 5 and even mortality. 2 The latter publications have received an enormous public reaction and even the Food Drug Administration has questioned the use of aprotinin.* These studies are still under discussion due to the statistically significant differences in baseline characteristics which had to be corrected by propensity score adjustment. This always leaves unanswered questions about an unmeasured selection which might have led to the higher incidences of adverse outcomes. 16 As previously described, aprotinin has a high affinity to the kidneys and may lead to disturbances in kininsynthesis and release, renal afferent vasoconstriction, and macro-and microvascular thrombosis. 17, 18 The phenomenon of arterial vasoconstriction with a probable intravascular thrombosis has also been observed in an animal model in the coronary 19 and femoral arteries. 20 However, the underlying mechanism is still unclear. In our study, there was neither a difference in postoperative renal dysfunction nor in the requirement for dialysis between the two treatment groups of the entire population. We set the criteria for postoperative renal dysfunction at a low serum creatinine level, (Ͼ1.3 mg/dL ϭ 115 mol/L) accompanied by an increase from baseline (Ն0.5 mg/dL ϭ 44 mol/L) to detect even milder forms of dysfunction. The overall incidence of dialysis between 5%-6% is well within the range of the literature, 1, 5 especially in view of the inclusion of high risk patients in our cohort. Contrary to the results of Group ALL, we found a significantly higher rate of renal dysfunction with aprotinin in the CABG subgroup. Although not reaching significance, the percentage of renal failure was twofold compared to Group T. Our data support previous findings of an increased risk of renal complications in patients receiving aprotinin during primary CABG surgery. 1, 5 The CABG and HIGH RISK subgroups were defined by similar criteria as in other studies, which described higher incidences of myocardial infarction 1 and death after aprotinin.
2 † Two recently published retrospective analyses of large CABG cohorts also reported, an increased risk for in-hospital death 6 and reduced long-term survival 7 among aprotinin recipients. We recorded a higher rate of myocardial infarctions in the CABG patients as well. Additionally, there was a tendency for more short-term mortalities in both CABG and HIGH RISK subgroups. The lack of significance might be related to the limited number of patients and fatal events. Nevertheless, 1-yr mortality was significantly increased after aprotinin treatment in the HIGH RISK patients. The finding of an increased mortality with aprotinin in patients at high risk for bleeding is in agreement with the results of the interim analyses of the BART study, which led to the suspension of marketing aprotinin. ‡ Another major finding of our study is the much higher rate of seizures after administration of tranexamic acid. Tranexamic acid has been shown to have an epileptogenic effect if it is applied topically to the cortex, 21, 22 intrathecally 23 or even IV in animals. 22 The suspected mechanism is a ␥-aminobutyric acid-driven inhibition of the central nervous system. 24 Some neurosurgical studies have shown a higher incidence of cerebral vasospasm after topical use of tranexamic acid in patients suffering from subarachnoid hemorrhage, 25 and also in an animal model. 26 Our finding might be related to tranexamic acid-induced vasoconstriction and to concomitant microcirculatory disturbances.
The pathomechanism of seizures detected in our study is not yet determined. They occurred almost exclusively after open heart surgery, in VALVE and HIGH RISK patients receiving tranexamic acid. Therefore, it seems reasonable that this complication was associated with the different management of these patients. One possible explanation is the electrolyte change due to the administration of crystalloid cardioplegia during valve surgery; another is the possible effect of microbubbles, which inevitably remain after closing the heart. Additionally, in the VALVE subgroup, the tranexamic acid patients had renal failure and persistent atrial fibrillation more frequently. These complications might have resulted in the tendency towards more short-term mortalities in this subgroup after tranexamic acid treatment. Since there are no large studies focusing on the safety of tranexamic acid, especially in valve surgery, this should be a topic of future research.
LIMITATIONS
Our study compared data of two chronologically close patient cohorts. Therefore, the risk of unrecognized changes in practice is reduced to a minimum, but it cannot be excluded completely. However, due to the study design and the fact that the known variables were comparable, we assumed that the groups matched well and the unknown variables were also comparable.
There were a considerable number of consecutive patients in total and the sample size exceeded the calculated sample size for a power of 0.8 in all the †www.fda.gov/cder/drug/early_comm/aprotinin.htm, last ac- subgroups. However, we cannot exclude that the study did not have enough power to detect all the differences between the treatment groups. Comparative trials powered for important clinical end-points are needed before any antifibrinolytic drug is routinely prescribed for a large number of patients. 27 Although we made multiple comparisons in our analyses, we did not adjust the P value because doing so would have increased the chance of making Type II errors. 28 Since our focus was on the possible side effects of antifibrinolytics, this appeared not to be prudent. Nevertheless, even with correction for multiple comparisons, the increased rate of seizures with tranexamic acid in valve surgery is a main finding of our study.
CONCLUSIONS
The blood-sparing effect of aprotinin after cardiac surgery was superior to that of tranexamic acid, but the clinical relevance of this remains questionable. The benefit of the blood-sparing effect has to be balanced against the potential risks of antifibrinolytic drugs.
Aprotinin was associated with a higher incidence of complications after primary CABG surgery and a higher 1-yr mortality in HIGH RISK patients compared to tranexamic acid. In addition, this is the first study reporting the detrimental effects of tranexamic acid after valve surgery.
Our results show that both antifibrinolytic drugs bear risks of adverse effects that might worsen outcome. Administration of aprotinin should be avoided in CABG and HIGH RISK patients. Tranexamic acid should not be used in open heart procedures until the mechanism of the side effects is clear.
